FindTrial
Sign In

Investigate the Dosimetric Profile of Stereotactic Ablative Radiotherapy (SABR) for Different Numbers of Lesions in the Lungs. A comparison Between VMAT and IMPT

Investigate the Dosimetric Profile of Stereotactic Ablative Radiotherapy (SABR) for Different Numbers of Lesions in the Lungs. A comparison Between VMAT and IMPT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093912
Enrollment
Unknown
Registered
2024-12-13
Start date
2023-12-01
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple primary lung cancer (MPLC) and multiple metastatic lung cancer (MIM)

Interventions

VMAT Group:NA
IMPT Group:NA

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. There are 1~6 primary or metastatic lesions in the lungs, and the lesion boundary is clear; 2. The scope of CT scan includes complete bilateral lung; 3. Age range: 30 years old (inclusive) to 70 years old (inclusive);

Exclusion criteria

Exclusion criteria: 1. History of previous lung surgery; 2. Structural abnormalities of both lungs caused by various reasons.

Design outcomes

Primary

MeasureTime frame
Dose parameters of lungs;Dmax of bronchia;—

Secondary

MeasureTime frame
Dmax of esophagus;NTCP value of radiation pneumonitis;Dmax of spinal cord;Dose parameters of heart;The EAR of radiotherapy induced secondary cancer;—

Countries

China

Contacts

Public ContactXianshu Gao

Peking University First Hospital

gao7777@139.com+86 10 83575239

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026